Phrases and practices that should prompt more scrutiny, not less.
• “Generic” of a branded GLP-1; “same as” the brand.
• “FDA-approved” on a compounded product or pharmacy.
• “Clinically proven” for the compounded formulation.
• No real medical evaluation; product without a prescription.
• Countdown timers and “today only” pressure.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.